414 related articles for article (PubMed ID: 3113763)
1. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Tobert JA
Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
[TBL] [Abstract][Full Text] [Related]
3. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Hoeg JM; Brewer HB
JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
[TBL] [Abstract][Full Text] [Related]
9. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
[TBL] [Abstract][Full Text] [Related]
10. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
11. The relationship between apolipoprotein B-100 and low-density lipoprotein cholesterol after treatment with an HMG CoA reductase inhibitor.
Levinson SS; Blevins RD; Smith MP; Rubinfire M; Maciejko JJ
Am J Clin Pathol; 1989 Oct; 92(4):479-83. PubMed ID: 2508466
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
[TBL] [Abstract][Full Text] [Related]
13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
14. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
18. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
[TBL] [Abstract][Full Text] [Related]
19. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
20. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
